Our website is made possible by displaying non-intrusive online advertisements to our visitors.
Please consider supporting us by disabling or pausing your ad blocker.
Most welcome Cheng. As always hope the best for Genting. Hopefully GenM able to sell off Miami assets and successful secured the Alzheimer's drug FDA soon..:)
Gent survived the MSCI index May review which is a good thing; exposure to foreign funds/institutions. The board has to work harder to keep its status in the MSCI index :)
Gens results is ok for me personally :) 2% top line and bottom line improvement compared to q4'24. q3 is the one to be watched closely with Laurus launching and bookings starting in May; recovering from the hotel room capacity disruptions. US assets - not feeling good about it. Catskills numbers not so good for q1 compared to q4. The strip area has a mixed performance for q1'25. RWLV q4'24 single digit ebitda margins and q1'25 maybe a challenge. Will need at least 6 to 9 months to measure the results/performance of the new board put in place in q4'24.
yes, Vin. Will continue to hold Gent and consider adding after each qr results if the numbers are decent. My current avg is ~3.4 and I didnt see anything from the last financial results that warrants me to exit; from ebitda and cash generated from ops if you will. After all, i have just bought it less than a year. I will reduce my position if the cash generated from the ops dips below 7bil per annum or two consecutive qtr achieving below 1.75bil per qtr. That's just my plan and my situation may not be the same as yours. Hope it helps.
you are welcome, Vin. No decision from UK MHRA yet for hmtm. As for rebuilding GenM, LKT has contained the damage within GenM with the latest move. RAV Bahamas shareholder dispute will hurt from the legal fees itself as the case will drag to 2026 at the minimum. LKT has to do more to shield Gent from GenM's US assets; its a drag for now particularly the funding to support GenM if the needs arises.
